VERACYTE, INC. quarterly report, Q3 FY2020

Veracyte, Inc. — Q3 2020 Form 10-Q

Reporting period: Three and nine months ended September 30, 2020. Veracyte is a genomic diagnostics company offering tests in thyroid, lung, interstitial lung disease and breast cancer; most historical revenue came from Afirma testing.

Financial results

Amounts are in millions of dollars except per-share data and test volumes.

MetricQ3 2020Q3 2019Nine months 2020Nine months 2019
Total revenue$31.1$31.0$82.9$90.6
Gross margin67%Not stated64%Not stated
Operating loss$(4.1)$(1.8)$(27.3)$(6.9)
Net loss$(4.1)$(0.7)$(26.9)$(5.1)
Basic and diluted loss per share$(0.08)$(0.02)$(0.52)$(0.11)
Operating cash flow$1.8Not stated$(12.0)$(5.0)
  • Q3 revenue comprised testing revenue of $28.3 million, product revenue of $2.0 million and biopharmaceutical revenue of $0.8 million. There was no collaboration revenue.
  • For the nine-month period, testing revenue was $70.5 million, product revenue $7.1 million and biopharmaceutical revenue $5.3 million.
  • At September 30, cash and cash equivalents were $345.1 million; total current assets were $370.3 million and current liabilities $13.9 million. Management said existing cash, the available credit line and expected revenue should cover anticipated requirements for at least 12 months from the filing date.
  • Debt principal outstanding was approximately $1, with a $0.8 million end-of-term obligation recorded; a $1.2 million final payment is due in 2022. The $10 million revolving facility was undrawn. The company reported covenant compliance.
  • Total liabilities were $31.4 million and stockholders’ equity was $422.7 million. The company reported an accumulated deficit of $273.6 million.

Material changes versus comparable periods

  • Q3 revenue was essentially unchanged year over year, while net loss widened to $4.1 million from $0.7 million. Testing revenue grew 6% and reported genomic classifier volume increased 3% to 10,242; Prosigna contributed $2.0 million of product revenue.
  • Nine-month revenue declined 8%, primarily as reported classifier volume fell 9% amid COVID-19 disruption and prior-year biopharmaceutical and collaboration milestones/data revenue was higher. Prosigna, newly commercialized after the NanoString transaction, contributed $7.1 million.
  • Nine-month net loss increased to $26.9 million from $5.1 million. Operating expenses rose 13% to $110.3 million, including higher R&D, G&A and intangible amortization. Nine-month operating cash use increased to $12.0 million from $5.0 million.
  • An August 2020 public offering of 6.9 million shares generated $193.8 million net proceeds. Cash and cash equivalents increased from $159.3 million at year-end 2019 to $345.1 million.

Outlook, commentary and risks

  • Management reported recovery in testing volumes after an April low: Q3 reported volume was up 90% sequentially and 3% year over year. The filing gives no numerical full-year revenue or earnings guidance and emphasizes that COVID-19 makes forecasting uncertain.
  • Management planned four 2021 product introductions: a nasal-swab lung classifier, Percepta Atlas, Envisia on the nCounter platform, and LymphMark if FDA De Novo classification is granted. These are plans, not guaranteed launches.
  • COVID-19 reduced patient activity and sample volumes, and management cited October supply interruptions involving plastic sample-processing materials. The company also recorded a $1.1 million supplies write-down for potentially expiring reagents tied to anticipated lower volumes.
  • Other key risks include dependence on Afirma and a limited number of payers, reimbursement and Medicare-rate uncertainty, reliance on single-source suppliers and TCP for cytopathology, regulatory and clinical-development uncertainty, and execution risks integrating NanoString assets and expanding internationally.
  • NanoString-related contingent consideration was revalued to $6.4 million, generating $0.3 million of expense; milestone achievement was not forecast within the next 12 months. The company disclosed no pending legal proceeding expected to have a material adverse effect.
  • Management expects ongoing losses. It may need additional financing if revenue or cash generation falls short; equity financing could dilute shareholders. The filing reports no off-balance-sheet arrangements.

Important facts for investors to verify

  • Whether testing volumes and revenue sustain their recovery, and the extent to which COVID-19 or supply constraints affect operations.
  • Reimbursement levels and payment outcomes, including the new Medicare pricing for Envisia and pricing for Afirma-related codes.
  • Prosigna growth and progress integrating the NanoString platform, including whether planned product launches occur on time and obtain required approvals.
  • Cash use, ongoing losses, dilution from equity issuance, and the timing and terms of the $1.2 million debt-related payment.
  • Whether the $6.4 million contingent consideration milestones are achieved and how estimates or remeasurement affect reported expenses.